Peptibase
Hormonal

Pegvisomant

Also known as: Somavert

FDA Approved
Share:

Key Facts: Pegvisomant

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Acromegaly
Administration
Subcutaneous injection daily
Typical Dose
10-30 mg daily
Frequency
Once daily
Evidence Level
FDA Approved
Duration
Long-term / chronic use
Also Known As
Somavert

What to Expect

A GH receptor antagonist that blocks growth hormone action. Used for acromegaly when surgery and somatostatin analogs fail to normalize IGF-1.

Mechanism of Action

Pegvisomant is a modified GH analog that binds GH receptors but prevents receptor activation and signaling. It directly blocks GH action rather than suppressing GH secretion, effectively normalizing IGF-1 levels.

Research Summary

Most effective medical therapy for normalizing IGF-1 in acromegaly (~90% achieve normal IGF-1). Does not shrink tumors. Often combined with somatostatin analogs. PEGylation extends half-life for daily dosing.

Clinical Status:FDA Approved - Acromegaly
Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

10-30 mg daily

Range

10-40 mg daily

Frequency

Once daily

GH receptor antagonist for acromegaly. Prescription only. Requires monitoring of liver function.

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

Duration

Long-term / chronic use

Administration

Subcutaneous injection daily

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Infection
  • ●Pain
  • ●Nausea
  • ●Injection site reactions
  • ●Liver toxicity (rare but serious)
  • ●Hypoglycemia in diabetics
  • ●FDA approved (Somavert)

References

Related Peptides

Peptides commonly compared with Pegvisomant or used in similar applications.

Gonadorelin

FDA

A synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.

Hormonal

Lanreotide

FDA

A long-acting somatostatin analog similar to octreotide. FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.

Hormonal

Macimorelin

FDA

An oral ghrelin mimetic used to diagnose adult growth hormone deficiency. The first FDA-approved oral GH stimulation test.

Hormonal

Oxytocin

FDA

A naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.

Hormonal

Leuprolide

FDA

A GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

Hormonal

Desmopressin

FDA

A synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.

Hormonal
How to Use PegvisomantPegvisomant AlternativesCompare with SimilarBrowse All Peptides

Want updates on Pegvisomant research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Educational Information Only

This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.

Back to all peptides